Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | NCS1 | P62166 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 9/20 | 0.39 |
| ▸ | ILK | Q13418 | 2/20 | 0.38 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.37 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19828320 | 0.83 | DYRK1A (0.41) | DYRK1AP2RY2TRPV1ALOX5NCS1 | |
| SCHEMBL7956829 | 0.76 | DYRK1A (0.50) | DYRK1ATRPV1ALOX5NCS1AKR1B1 | |
| SCHEMBL8133603 | 0.74 | DYRK1A (0.41) | DYRK1ATRPV1ALOX5NCS1AKR1B1 | |
| SCHEMBL21048429 | 0.72 | ALOX5 (0.59) | DYRK1AP2RY2TRPV1ALOX5NCS1 | |
| SCHEMBL9743459 | 0.71 | ABL1 (0.39) | DYRK1A | |
| SCHEMBL19828322 | 0.69 | ILK (0.39) | DYRK1ATRPV1ALOX5NCS1AKR1B1 | |
| SCHEMBL3613102 | 0.67 | DYRK1A (0.56) | DYRK1ATRPV1ALOX5NCS1AKR1B1 | |
| Lithium Ion SCHEMBL31084584 | 0.67 | DYRK1A (0.56) | DYRK1ATRPV1ALOX5NCS1AKR1B1 | |
| SCHEMBL21048414 | 0.67 | ACP3 (0.39) | — | |
| SCHEMBL3642935 | 0.66 | DYRK1A (0.58) | DYRK1ATRPV1ALOX5NCS1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10315990-B2 | Isothiocyanate compounds and isothiocyanate XPO1 protein inhibitor drugs thereof | DRIVINGFORCE THERAPEUTICS (CN) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10315990-B2 | Isothiocyanate compounds and isothiocyanate XPO1 protein inhibitor drugs thereof | XPO1, XPOT, XPO4 | DYRK1A 3977/4885P2RY2 4325/4885TRPV1 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.